Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes
暂无分享,去创建一个
M. Sabatine | E. Braunwald | D. Morrow | S. Murphy | B. Scirica | T. Omland | M. Bjerre | A. Flyvbjerg | M. Bonaca | R. Røysland
[1] R. Burrow,et al. Heart , 2013, Feline Soft Tissue and General Surgery.
[2] M. Böhm,et al. Osteoprotegerin Predicts Progression of Chronic Heart Failure: Results From CORONA , 2011, Circulation. Heart failure.
[3] G. Andersen,et al. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size , 2011, Heart.
[4] Ewout W Steyerberg,et al. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.
[5] E. Benjamin,et al. Biomarkers of the Osteoprotegerin Pathway: Clinical Correlates, Subclinical Disease, Incident Cardiovascular Disease, and Mortality , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[6] L. Tavazzi,et al. Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. , 2010, American heart journal.
[7] D. Atar,et al. Osteoprotegerin concentrations and prognosis in acute ischaemic stroke , 2010, Journal of internal medicine.
[8] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[9] A. Nordström,et al. Osteoprotegerin Promotes Fibrous Cap Formation in Atherosclerotic Lesions of ApoE-Deficient Mice—Brief Report , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[10] F. Saad,et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.
[11] D. Levy,et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. , 2009, The American journal of cardiology.
[12] J. Golledge,et al. Osteoprotegerin, vascular calcification and atherosclerosis. , 2009, Atherosclerosis.
[13] J. Herlitz,et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. , 2008, Journal of the American College of Cardiology.
[14] M. Drazner,et al. Plasma Osteoprotegerin Levels in the General Population: Relation to Indices of Left Ventricular Structure and Function , 2007, Hypertension.
[15] A. Skene,et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. , 2007, JAMA.
[16] A. Khera,et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). , 2007, The American journal of cardiology.
[17] Fred S Apple,et al. Universal definition of myocardial infarction. , 2007, Journal of the American College of Cardiology.
[18] P. Secchiero,et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. , 2006, The American journal of pathology.
[19] P. Buttner,et al. Assessment of a Serum Assay for Quantification of Abdominal Aortic Calcification , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[20] Brian J. Bennett,et al. Osteoprotegerin Inactivation Accelerates Advanced Atherosclerotic Lesion Progression and Calcification in Older ApoE−/− Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[21] A. Skene,et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. , 2006, American heart journal.
[22] G. Christensen,et al. Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure , 2005, Circulation.
[23] K. Dickstein,et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. , 2004, Journal of the American College of Cardiology.
[24] P. Pietschmann,et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. , 2003, Bone.
[25] M. Sabatine,et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. , 2003, Journal of the American College of Cardiology.
[26] KatsuhitoMori,et al. Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease , 2002 .
[27] Y. Ikari,et al. Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease , 2002, Circulation.
[28] T. Shigematsu,et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] P. Geusens,et al. Differential Expression of Bone Matrix Regulatory Proteins in Human Atherosclerotic Plaques , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[30] M. Sabatine,et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.
[31] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[32] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.